Skip to content
DataLookout
Menu

Thyroid Cancer clinical trials

Get alerts when Thyroid Cancer trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-14

What changed in the last 30 days

28 trials changed in the last 30 days: 2 stopped, 8 with notable changes, 18 with minor changes only.

  1. Minor: BCB RIV · Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department Study completion pushed from Oct 2029 to Oct 2036 Institut du Cancer de Montpellier - Val d'AurelleNot applicable NCT04104529
  2. Minor: FNA inadequacy · Factors Influencing Inadequacy in Rapid Onsite Evaluation of Ultrasound Guided Fine Needle Aspiration (FNA) Samples of Thyroid Nodules Trial completed Assiut UniversityNot applicable NCT06984991
  3. Minor: Application of Electrical Stimulation in Postoperative Pain Management of Thyroid Surgery Interventions modified Xiaonan HuangNot applicable NCT06931743
  4. Minor: 8 trials marked Unknown by the registry's verification sweep Changed Registry verification sweep8 trials
    1. Minor: JK08 · Unresectable Locally Advanced or Metastatic Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting Salubris Biotherapeutics IncPhase 1/2 NCT05620134
    2. Minor: QUANTUM · Quest to Analyze One Thousand Humans Meditating Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation Tobias Moeller-BertramNot specified NCT06583395
    3. Minor: Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Massachusetts General HospitalPhase 2 NCT05668962
    4. Minor: Treatment of Differentiated Thyroid Carcinoma with Anlotinib Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting Yansong LinPhase 2 NCT05007093
    5. Minor: Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Peking Union Medical College HospitalEarly Phase 1 NCT06632860
    6. Minor: EMIRATES Study Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Royal Marsden NHS Foundation TrustNot specified NCT06855680
    7. Minor: Prevalence of Osteo-metabolic Complications · Thyroid Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting IRCCS San RaffaeleNot specified NCT06627998
    8. Minor: Cognition and QoL After Thyroid Surgery Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2023); last known: Recruiting Karolinska University HospitalNot specified NCT05088187
  5. Minor: PURE · Nasal Steam Therapy for Post-extubation Respiratory Events Trial completed Ilsan Cha hospitalNot applicable NCT06840106
  6. Notable: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab · Advanced or Metastatic Malignancy or Other Benign Disease Results posted: Nov 5, 2026 M.D. Anderson Cancer CenterPhase 1 NCT01552434
  7. Minor: DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules Primary and study completion pushed from Oct 22, 2026 to Jan 21, 2027 City of Hope Medical CenterNot applicable NCT05229341
  8. Notable: CAMPERR · CfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease Primary completion pushed from Mar 2026 to Dec 31, 2026 Adela, IncNot specified NCT05366881
  9. Notable: ACC-1898 · Advanced Solid Tumors Primary completion pushed from Jun 2027 to Jun 2028 AccSalus Biosciences, Inc.Phase 1 NCT07252661
  10. Notable: Trametinib in Combination With Paclitaxel · Anaplastic Thyroid Cancer Primary and study completion pushed from Sep 2026 to Sep 2027 Memorial Sloan Kettering Cancer CenterEarly Phase 1 NCT03085056
  11. Notable: REPOTHYROID-II · Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial Enrollment reopened Radboud University Medical CenterPhase 1 NCT07485569
  12. Notable: PPB/DICER1 Registry Primary completion pushed from Dec 6, 2030 to Dec 6, 2031 Children's Hospitals and Clinics of MinnesotaNot specified NCT03382158
  13. Stopped: Personalized Treatment in Thyroid Disorders Recruitment suspended Johns Hopkins UniversityNot applicable NCT03517579
  14. Notable: Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer Primary completion pushed from Oct 1, 2026 to Oct 1, 2028 Children's Hospital of PhiladelphiaPhase 2 NCT05783323
  15. Minor: Cabozantinib Compared With Placebo · Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Study completion pushed from Jul 31, 2026 to Jul 31, 2027 ExelixisPhase 3 NCT03690388
  16. Minor: Biodistribution of an Imaging Tracer (68Ga-FAPi-46) · Solid Tumors or Hematologic Cancers Primary completion date changed from estimate of Sep 6, 2026 to Jun 23, 2026 Jonsson Comprehensive Cancer CenterPhase 1 NCT07118176
  17. Notable: STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Primary completion pushed from Sep 2, 2031 to Sep 2, 2032 Jonsson Comprehensive Cancer CenterNot applicable NCT07612293
  18. Stopped: Dabrafenib, Trametinib, and IMRT · BRAF Mutated Anaplastic Thyroid Cancer Recruitment suspended City of Hope Medical CenterPhase 1 NCT03975231
  19. Minor: Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients Primary and study completion pushed from Oct 31, 2026 to Jan 5, 2027 Novartis PharmaceuticalsNot specified NCT07770074
  20. Minor: MDX2001 · Advanced Solid Tumors Enrollment increased: 285 → 330 participants ModeX Therapeutics, An OPKO Health CompanyPhase 1/2 NCT06239194
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-03 NCT07911761 Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma Mansoura University new
2026-11-03 NCT07911891 Oral Mecobalamin for TKI-Associated Hand-Foot Syndrome in Advanced Thyroid Cancer Li Zhihui new Phase 2
2026-09-10 NCT07812779 Thyroid Health Outcomes Registry for Surgery Pirogov Russian National Research Medical University new
2026-08-20 NCT07776262 Safety and Efficacy of Cryoablation for Thyroid Tumors Yukun Luo new

Active trials by phase

Early Phase 1
5
Phase 1
27
Phase 1/2
13
Phase 2
64
Phase 2/3
5
Phase 3
17
Phase 4
8
Not charted: 188 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Thyroid Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials